Presentation is loading. Please wait.

Presentation is loading. Please wait.

Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study by Marius Flasinski, Kira Scheibke, Martin Zimmermann,

Similar presentations


Presentation on theme: "Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study by Marius Flasinski, Kira Scheibke, Martin Zimmermann,"— Presentation transcript:

1 Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study by Marius Flasinski, Kira Scheibke, Martin Zimmermann, Ursula Creutzig, Katarina Reinhardt, Femke Verwer, Valerie de Haas, Vincent H. J. van der Velden, Christine von Neuhoff, C. Michel Zwaan, Dirk Reinhardt, and Jan-Henning Klusmann BloodAdv Volume 2(13): July 10, 2018 © 2018 by The American Society of Hematology

2 Marius Flasinski et al. Blood Adv 2018;2:1532-1540
© 2018 by The American Society of Hematology

3 Overview of the TMD Prevention 2007 study.
Overview of the TMD Prevention 2007 study. (A) Treatment plan of the TMD07 study. (B) Flowchart of patients enrolled in the TMD07 study. Marius Flasinski et al. Blood Adv 2018;2: © 2018 by The American Society of Hematology

4 Outcome of TMD07 patients compared with the historical control.
Outcome of TMD07 patients compared with the historical control. (A) OS. (B) EFS. (C) CI of early death. Five-year probabilities are given in panels A and B. Marius Flasinski et al. Blood Adv 2018;2: © 2018 by The American Society of Hematology

5 Outcome of symptomatic TMD07 patients (intention-to-treat at diagnosis) compared with symptomatic patients in the historical control. Outcome of symptomatic TMD07 patients (intention-to-treat at diagnosis) compared with symptomatic patients in the historical control. (A) OS. (B) EFS. (C) CI of early death. Five-year probabilities are given in panels A and B. Marius Flasinski et al. Blood Adv 2018;2: © 2018 by The American Society of Hematology

6 Progression to ML-DS. Progression to ML-DS. CI of ML-DS: (A) TMD07 patients compared with the historical control. (B) Per protocol analysis: Treated TMD07 patients compared with asymptomatic, MRD-negative, untreated TMD07 patients and to the historical control. (C) MRD-positive TMD07 patients compared with MRD-negative TMD07 patients in week 12. Five-year probabilities are given in panels A through C. Marius Flasinski et al. Blood Adv 2018;2: © 2018 by The American Society of Hematology


Download ppt "Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study by Marius Flasinski, Kira Scheibke, Martin Zimmermann,"

Similar presentations


Ads by Google